The German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry of Economic Affairs (BMWi), will advise on the development and implementation of Ada’s US market strategy with its experienced mentor team and extensive network of partners and industry experts.
"The US has become one of our fastest growing markets," said Daniel Nathrath, CEO and Founder of Ada. "Our operational expansion, along with our new team of medical advisors and collaboration with GALS, will help us identify the most effective ways to integrate our solution into the US healthcare ecosystem and maximise the impact we deliver to patients."
"Healthcare systems are under extreme pressure," added Dr. Claire Novorol, Founder and Chief Medical Officer of Ada. "There's a tremendous potential for Ada’s assessment technology to improve personalized health support and positively transform the way in which patients and doctors interact, in the US and globally."
"We believe Ada is positioned to become a leading global health management player," commented Christoph Lengauer, CEO of the German Accelerator. "GALS is excited to be collaborating with Ada on this expansion into the US. We will leverage our deep industry network and expertise to support their continued success."
"Ada has developed one of the most highly innovative and sophisticated health assessment tools on the market," commented Thomas Kiessling, GALS mentor and former Chief Product and Innovation Officer at Deutsche Telekom. "We see many potential opportunities where Ada can add value to the US life sciences industry."
Ada's personal health companion interacts with patients via a conversational interface to identify their symptoms and suggest possible causes. As a follow up, patients in the UK have the option to remotely consult with a general practitioner through Ada's Doctor Chat. The German version of the App was launched early this month and aims to follow the extended UK model in the near future.
As part of the European Union's Horizon 2020 Research and Innovation Programme (Ada2020), Ada has also developed a decision support tool for general practitioners and specialists. After years of years refining our medical content and reasoning capabilities, along with continuous learning from medical experts, Ada provides an advanced decision support system and is now able to support doctors with their diagnosis for even the most complex and rare cases.
About Ada
Ada Health is an innovative health technology company that believes everyone in the world should have access to quality, personalized health information and care. Developed by a team of doctors, scientists and engineers, Ada Health launched its conversational health companion app to empower people with personalized medical insights and identify appropriate next steps. Supported by a sophisticated AI engine and curated medical knowledge base, Ada also augments doctors by providing earlier health information and decision support. Ada's personal health companion app is available on iOS and Android and has been one of the fastest growing medical apps in 2017, ranked #1 in over 130 countries. You can find more information about Ada at www.ada.com.
About the German Accelerator Life Sciences
The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi) with the goal of helping German startups and young companies succeed in the global marketplace. GALS, centrally located and highly connected in the world’s leading life sciences innovation hub in Cambridge, Massachusetts, offers support in multiple areas: from operational assistance to high end mentoring and strategic guidance by experienced industry experts and key opinion leaders.